Skip to content
Licensed Unlicensed Requires Authentication Published by De Gruyter September 17, 2011

Effects of recombinant human growth hormone on protein turnover in the fasting and fed state in adolescents with Crohn disease

  • Tamara S. Hannon EMAIL logo , Linda A. DiMeglio , Marian D. Pfefferkorn , Aaron E. Carroll and Scott C. Denne

Abstract

The primary purpose of this study was to test whether recombinant human growth hormone (rhGH) supplementation would enhance protein synthesis and accretion of lean body mass. Eight adolescents (six males and two females; 17.2±2.6 years; age range, 13.7–21.2 years) participated in a randomized double-blind placebo-controlled cross-over trial of rhGH. We employed stable isotopes to measure proteolysis and protein synthesis during fasting and fed conditions during two 6-month treatment conditions. We also measured bone mineral density (BMD), markers of bone turnover, and body composition. Whole-body proteolysis, phenylalanine catabolism, and protein synthesis did not differ during treatment with rhGH vs. placebo. Enteral nutrition suppressed proteolysis and increased protein synthesis similarly during placebo and rhGH treatments. We conclude that rhGH is unlikely to provide sufficient metabolic benefit to warrant its use as an adjunct treatment in clinically stable adolescents with Crohn disease. A high prevalence of vitamin D deficiency and suboptimal BMD existed, which deserves further investigation and clinical attention.


Corresponding author: Tamara S. Hannon, MD, Riley Hospital for Children, Rm 5960, 702 Barnhill Dr, Indianapolis, IN 46202, USA Phone: +1 317 9447389, Fax: +1 317 9443882

Received: 2011-6-13
Accepted: 2011-8-16
Published Online: 2011-09-17
Published in Print: 2011-10-01

©2011 by Walter de Gruyter Berlin Boston

Downloaded on 28.3.2024 from https://www.degruyter.com/document/doi/10.1515/JPEM.2011.308/html
Scroll to top button